Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Active

PAR-28-042Grant

Response Deadline11/17/2029, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.

General Info

NCI funding for analytical and clinical validation of cancer biomarkers and assays.

Agency

National Institutes Of Health → National Cancer Institute

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation

PostedNov 3

Solicitation

Response DeadlineNov 17

Submission deadline

Response Deadline

11/17/2029, 12:00:00 AM UTCin about 3 years

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyNational Institutes Of Health → National Cancer Institute

ContactsNo contacts available

OfficeUSA

Organization / AgencyNational Institutes Of Health → National Cancer Institute

Office AddressUSA

ContactsNo contact information available

Full Description

Show more

The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.

Similar Contracts

Same NAICS industry code

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-014

The National Institutes of Health (NIH) issued solicitation RFA-AI-28-014 to establish centers focused on the systems-level understanding of the links between infectious pathogens, inflammatory pathways, and chronic diseases. The program supports two types of centers: Chronic and Infectious Diseases Systems Biology Centers (CIDSB), which examine the bidirectional link between chronic and infectious diseases, and Systems Biology Inflammation Centers (SBI), which focus on the role of inflammation in chronic diseases to identify precision medicine targets. The primary goals are to develop predictive computational models for disease progression, discover novel drug targets and biomarkers, and create harmonized, FAIR-compliant cross-disease datasets. The total program funding is 26 million dollars, with an expected 10 awards and an individual award ceiling of 2.5 million dollars. Applications must be submitted electronically via Grants.gov by February 18, 2027. The proposal structure is multi-component, requiring an overall section, an administrative core, a data and modeling core, and a biospecimen collection and processing core, with additional requirements for research projects and optional cores depending on the center type. Evaluation is based on an overall impact score focusing on significance and the qualifications of the investigators. Awardees must comply with strict cybersecurity incident reporting requirements, notifying the HHS awarding agency within 48 hours of discovery, and must adhere to rigorous biosafety and human subjects protection standards. Applicants must maintain active SAM registration and UEI identifiers to be eligible for funding.

National Institutes Of Health

POSTED

about 19 hours ago

DEADLINE

In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.

National Institutes Of Health

POSTED

DEADLINE

in over 2 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

Solicitation PAR-28-042, issued by the National Institutes of Health under the Department of Health and Human Services, is a funding opportunity designed to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer. The program focuses on tools for cancer detection, diagnosis, prognosis, monitoring, and the prediction of treatment response or toxicity. Funding is available through either a phased UH2/UH3 mechanism or a standalone UH3 mechanism to facilitate laboratory optimization and clinical validation using human samples. Key deliverables include the demonstration of assay results associated with clinical endpoints, the establishment of statistical cut-off values, and the definition of sensitivity and specificity. All clinical laboratories must adhere to CLIA, GLP, or ISO 17025 standards. Awards are determined via a peer review system based on an overall impact score, evaluating the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Specific evaluation criteria include the clarity of milestones for transitioning from UH2 to UH3 phases and the adequacy of commercialization plans. Eligible applicants include small businesses, for-profit organizations, higher education institutions, and 501(c)(3) nonprofits. Applicants must maintain active registrations in SAM.gov, eRA Commons, and Grants.gov. Additionally, recipients must comply with strict cybersecurity incident reporting requirements, notifying the agency within 48 hours of discovery, and ensure all human subject protocols are reviewed by an Institutional Review Board or Independent Ethics Committee.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institute of Neurological Disorders and Stroke, under the National Institutes of Health, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias. This initiative covers a broad range of conditions, including Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program is designed to advance the translational pipeline from initial therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Eligible activities include the optimization of delivery systems and editing constructs, the assessment of bioactivity and pharmacokinetics, and the demonstration of in vivo efficacy. Additionally, the funding supports safety pharmacology, toxicology studies, and the creation of scalable manufacturing processes and quality attributes that meet regulatory standards. This solicitation was posted on November 3, 2026, with a response deadline of October 11, 2028.

National Institute Of Neurological Disorders And Stroke

POSTED

DEADLINE

in almost 2 years

Insect Taxonomy and Identification SpecialistThis subcontract opportunity is for an Insect Taxonomy and Identification Specialist to support prime contractors on USDA Forest Health Protection projects through the Northern Research Station. The selected specialist will perform professional taxonomic screening and identification of raw insect trap samples, specifically focusing on species-level identification of wood-boring beetles and wood wasps, as well as identifying Coleoptera and select Hemiptera to the lowest taxonomic level. The work requires the use of taxonomic keys and high-powered microscopy, with final identification reports delivered in Word or PDF format. The solicitation was posted on November 2, 2026, with a response deadline of December 3, 2026. Classified under NAICS code 541714, the performance of this contract is associated with zip code 26505. Interested parties can find further details via the provided government workspace link.

Northern Research Station

POSTED

DEADLINE

Sanger and High-Throughput DNA Sequencing ServicesThis subcontract for the National Institutes of Health Olao involves providing Sanger and high-throughput DNA sequencing services for prime contractors on NIH/NIEHS projects. The scope of work includes executing whole-plasmid sequencing on yeast colonies, plasmid DNA, and PCR-generated samples derived from recombinant, human, and rodent DNA sources. To ensure precision, the contractor must utilize automated DNA sequencers and PCR thermocyclers equipped with electronic barcode tracking, while maintaining Phred-equivalent quality scores greater than 20 and delivering secure data files. The project is categorized under NAICS code 541714 and will be performed in Durham, North Carolina. Interested parties should note the response deadline of November 12, 2026, for this specialized genomic services requirement.

National Institutes Of Health Olao

POSTED

DEADLINE

DNA Sequencing Service

Solicitation # PCA-NIEHS-00080

The National Institutes of Health, through the National Institute of Environmental Health Sciences, is issuing a Small Business Sources Sought notice for solicitation PCA-NIEHS-00080 to identify capable providers for an indefinite-delivery indefinite-quantity contract. The requirement is for DNA sequencing services and associated bioinformatics support, primarily utilizing Sanger sequencing with a smaller volume of high-throughput whole-plasmid sequencing. The estimated workload is between 2,000 and 3,000 samples per month, including yeast colonies, plasmid DNA, and PCR-generated samples from human and rodent species. The intended period of performance is five years from the date of award, with a potential six-month extension per FAR 52.217-8. The selected contractor must provide a web-based ordering and tracking system, all necessary sample collection and shipping materials, and a reliable transportation method for samples from the NIEHS campus in Research Triangle Park, North Carolina. Key technical requirements include maintaining a Phred-equivalent quality score greater than 20 for sequencing and ensuring successful PCR amplification produces a single DNA band of the expected size. The contractor is responsible for preserving remaining DNA for at least 180 days and returning unused primers to the government. Administrative requirements include submitting invoices within ten business days of the billing cycle and maintaining strict confidentiality of all sequencing data. This notice is specifically targeting small business concerns, including 8(a), SDB, WOSB, HUBZone, VOSB, and SDVOSB designations. Interested parties must submit a capability statement of no more than seven pages, including their UEI, TIN, and business size certification, to Luz Casey by November 12, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Clinical Trial Management and ExecutionThe Clinical Trial Management and Execution subcontract, issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, focuses on the operational and clinical execution of human subject research for FDA regulatory science projects. The selected provider will be responsible for managing patient recruitment, trial monitoring, and data collection across various clinical sites, ensuring all activities strictly adhere to Good Clinical Practice guidelines and Institutional Review Board approvals. Key deliverables for this engagement include the submission of clinical study reports, comprehensive patient data sets, and detailed trial outcome summaries. Interested parties should note that the response deadline for this opportunity is January 22, 2027, and the work falls under NAICS code 541714.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

More opportunities from National Institutes Of Health → National Cancer Institute

Same awarding agency

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

Solicitation # PAR-28-063

The National Cancer Institute is offering the Research Specialist Award (R50) under solicitation PAR-28-063 to support exceptional clinician scientists involved in NCI-funded clinical trials research. This award aims to create stable career paths for professionals who provide leadership in developing national clinical trials, implementing these trials within their own institutions, and serving on scientific review or monitoring committees. The program is specifically designed for those who wish to maintain a high level of influence and service within NCI clinical trials networks without serving as principal investigators on research project grants. By providing dedicated salary support and increased professional autonomy, the award ensures that these vital clinician scientists are not solely dependent on external funding or grants held by other individuals. This initiative is intended to sustain the overall NCI clinical trials enterprise by securing the continuity of experienced research careers. Applications for this federal opportunity are open until February 21, 2029.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

in over 2 years

Notice of Change: Grants Administration Information added for NCI's Participation on PA-27-036, NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed)

Solicitation # NOT-CA-26-019

This Notice of Change, identified by solicitation number NOT-CA-26-019, updates the NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) under PA-27-036. The primary purpose of this amendment is to incorporate specific Grants Administration Information regarding the National Cancer Institute's participation in the program. The update specifically modifies Section VII, Agency Contacts, to include the Office of Grants Administration for the National Cancer Institute as a financial and grants management contact. No other changes have been made to the original PA-27-036 guidelines. Interested parties can coordinate with the Center for Cancer Training or the Office of Grants Administration for further inquiries.

Administration of Public Health Programs

POSTED

DEADLINE

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Solicitation # RFA-CA-28-004

The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.

Blood and Organ Banks

POSTED

DEADLINE

Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)

Solicitation # PAR-28-014

The National Cancer Institute, under the National Institutes of Health, is soliciting applications for solicitation PAR-28-014 to investigate the causes and biological mechanisms of sporadic non-hereditary early-onset cancers in adults aged 18 to 49. The primary goal of this initiative is to understand the rising incidence of these cancers to improve prevention and control strategies. Research should specifically target environmental or lifestyle drivers across various demographics, the biological host responses involved, or the development of more effective methods for identifying high-risk individuals. This funding opportunity supports both standard research projects and exploratory or developmental studies through a grant award instrument, with clinical trials being optional. Interested parties must submit their applications by the deadline of October 12, 2029.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

in almost 3 years

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)

Solicitation # PAR-28-022

The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

in almost 3 years

Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)

Solicitation # RFA-CA-28-013

The National Cancer Institute, under the National Institutes of Health, is seeking meritorious proposals for the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative. This solicitation, identified as RFA-CA-28-013, aims to fund projects that critically and systematically evaluate scientific evidence regarding carcinogenic hazards to humans to better inform cancer research, control, and prevention efforts. Interested applicants must submit their proposals by the response deadline of February 10, 2027. This opportunity is categorized as an R01 grant, and it is explicitly noted that clinical trials are not allowed under this specific funding program.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Notice of Change in Application Due Date for RFA-CA-27-005 "Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)"

Solicitation # NOT-CA-26-020

This notice issued by the National Cancer Institute of the National Institutes of Health serves to amend the application timeline for the Glioblastoma Therapeutics Network clinical trial solicitation, RFA-CA-27-005. The primary modification is the addition of a second application due date on January 11, 2027, for new, renewal, resubmission, and revision applications. Under this new cycle, the scientific merit review is scheduled for June 2027, followed by an advisory council review in August 2027, with an earliest start date of December 2027. The expiration date for this specific window is January 12, 2027. All other terms and conditions of the original notice of funding opportunity remain unchanged.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)

Solicitation # PAR-28-057

The National Cancer Institute is soliciting applications under solicitation PAR-28-057 to establish the Management and Data Coordination Unit as a key scientific component of the Pancreatic Cancer Detection Consortium. This initiative focuses on the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions to identify high-risk patients, aligning with the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The selected unit will be responsible for providing critical infrastructure and collaborative support, including study design, protocol development, statistical analysis, and comprehensive data management. Additionally, the unit will oversee the coordination of biorepository building and provide the necessary organizational and logistics support to ensure the successful operation of the consortium. Applications must be submitted by the deadline of May 26, 2027.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 3 years

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS